IPOGrid
0002046386
IPO filing research
Medline Inc.
Surgical & Medical Instruments & Apparatus · MDLN
follow-on
trading
priced
Nasdaq Global Select Market
424B4
Medline Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: 424B4 on 2026-05-26. Current deal snapshot: exchange Nasdaq Global Select Market.
Filing Timeline
SEC EDGAR
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
First tracked pre-IPO filing for this issuer.
2026-05-26 · 0001193125-26-239247
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
First tracked pre-IPO filing for this issuer.
2026-05-21 · 9999999995-26-001735
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
60,000,000 shares
Class A · Exchange Nasdaq Global Select Market · Ticker MDLN · Over-allotment 9,000,000 · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the issuer will not receive any proceeds. · Flags units · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. is conducting an IPO with the ticker symbol MDLN on Nasdaq. The filing outlines financial data, including net sales of $7.35 billion for the three months ended March 28, 2026, and net income of $239 million. The company operates as a holding company with assets held through Medline Holdings, which underwent reorganization transactions. The filing references the 2025 Form 10-K for risk factors and includes details on share structures, including Class A common stock and Common Units. Tax implications for non-U.S. holders and underwriting agreements are noted.
2026-05-20 · 0001193125-26-231691
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
2026-04-17 · 0001193125-26-161061
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows EFFECT and confirms the priced prospectus.
Price $41.00 · 75,000,000 shares · Gross proceeds $3,075,000,000
Class A · Exchange Nasdaq · Ticker MDLN · Over-allotment 11,250,000 · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, and the company will not receive any proceeds · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
The current 424B4 filing for Medline Inc. provides pro forma consolidated financial data and details about share issuances related to the IPO. It outlines the shares outstanding, shares issuable upon exchange of Common Units, and equity grants under the 2025 Omnibus Incentive Plan. The filing also includes unaudited pro forma financial statements reflecting the Reorganization Transactions and IPO as if they occurred on specified dates.
2026-03-06 · 0001193125-26-096456
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1 and marks the registration effective.
Medline Inc. has received SEC approval for its IPO, with the registration statement effective as of March 4, 2026. The offering involves 75 million Class A common shares, with underwriters having an option to purchase additional shares. The company will not receive proceeds from the sale, which are managed by selling stockholders. The filing includes details on underwriting terms, exchange agreements for Common Units, and organizational structure.
2026-03-04 · 9999999995-26-000728
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS in the pre-IPO sequence.
75,000,000 shares
Class A · Exchange Nasdaq Global Select Market · Ticker MDLN · Over-allotment 11,250,000 · Selling stockholders only · Use of proceeds Selling stockholders are offering shares, with no proceeds to the company · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. is conducting an IPO, with pro forma financial data reflecting its reorganized structure as a holding company. The filing outlines share calculations, including Class A common stock issuance, Common Units conversions, and equity plans. Financials show growth in net sales and adjusted EBITDA, with detailed segment performance for Medline Brand and Supply Chain Solutions. The offering includes underwriters' options and employee equity grants.
2026-03-03 · 0001193125-26-086603
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
Begins the tracked draft filing sequence after 424B4.
Medline Inc. reported significant growth in net sales, operating income, and EBITDA in the current filing compared to previous periods. Net sales for 2023 increased by $1.78 billion (8.3%) to $23.23 billion, driven by U.S. Prime Vendor sales growth and organic volume increases. Segment performance showed strong results, with Medline Brand and Supply Chain Solutions segments both experiencing double-digit revenue and EBITDA growth. The company also highlighted improvements in gross profit margins and operating leverage, though challenges included litigation charges and tariff-related costs.
2026-02-09 · 0001193125-26-043051
424B4
priced
Final prospectus
Final prospectus filed after pricing with final deal terms.
Follows 8-A12B and confirms the priced prospectus.
Price $29.00 · 216,034,482 shares · Gross proceeds $6,264,999,978
Class A · Exchange Nasdaq · Ticker MDLN · Over-allotment 32,405,172 · Use of proceeds To acquire Common Units from Medline Holdings for debt repayment, general corporate purposes, and offering expenses, and to purchase equity interests from pre-IPO owners · Flags dual_class, units · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. reported strong financial performance in 2023 and 2024, with significant growth in net sales, operating income, and segment profitability. Net sales for 2023 increased 8.3% to $23.2 billion, driven by U.S. Prime Vendor sales growth and volume expansion. The Medline Brand segment saw a 20.9% increase in Segment Adjusted EBITDA, while Supply Chain Solutions improved margins through operating leverage. Recent nine-month results (through September 2025) highlight continued growth in both segments, with Medline Brand achieving a 25.4% EBITDA margin and Supply Chain Solutions expanding its margin to 5.5%.
2025-12-18 · 0001193125-25-323742
CERT
inactive
CERT
Pre-IPO filing captured from the SEC submission timeline.
First tracked pre-IPO filing for this issuer.
2025-12-17 · 0001354457-25-001276
8-A12B
effective
Exchange Act registration
Registration filed to list the securities under the Exchange Act ahead of trading.
Follows EFFECT and registers the class of securities for exchange listing.
Medline Inc. is registering its Class A common stock under Section 12(b) of the Securities Exchange Act of 1934, transitioning from its initial S-1 registration statement (File No. 333-291112) to a formal listing on Nasdaq. The filing incorporates by reference the prospectus from the S-1, which outlines the capital structure and securities details. No additional securities are being registered under Section 12(g).
2025-12-17 · 0001193125-25-321208
EFFECT
effective
SEC effectiveness notice
SEC declared the registration statement effective, allowing the offering to proceed.
Follows S-1/A and marks the registration effective.
Medline Inc. has received SEC approval for its IPO registration statement (Form S-1), confirming the effectiveness of its initial public offering. The company plans to issue 179 million Class A shares at an expected price range of $26.00-$30.00 per share. Proceeds will be used to acquire Common Units from Medline Holdings, LP for debt repayment, corporate purposes, and offering expenses. The offering includes underwriter options for additional shares and participation from cornerstone investors.
2025-12-16 · 9999999995-25-003786
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1/A filing.
Range $26.00 to $30.00 · 179,000,000 shares
Class A · Exchange Nasdaq · Ticker MDLN · Over-allotment 26,850,000 · Use of proceeds To acquire Common Units from Medline Holdings for debt repayment and general corporate purposes · Flags dual_class · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. reported strong financial performance in 2023 and 2024, with net sales increasing to $23.2 billion in 2023 and $24.5 billion in 2024. The company experienced significant growth in both U.S. and international markets, driven by volume expansion in Prime Vendor sales and strategic acquisitions. Operating income surged by 45.2% in 2023, and Segment Adjusted EBITDA margins improved across both Medline Brand and Supply Chain Solutions segments. The filing includes detailed financial results for nine months ended September 2025 and full-year 2024 data, reflecting continued operational growth and margin expansion.
2025-12-08 · 0001193125-25-311099
S-1/A
amended
Amended registration statement
Updated registration statement filed after SEC comments or deal changes.
Updates the prior S-1 filing.
A · Exchange Nasdaq Global Select Market · Ticker MDLN · Use of proceeds To acquire Common Units from Medline Holdings for debt repayment, general corporate purposes, and offering expenses · Flags dual_class · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, aiming to raise capital through the sale of shares. The offering involves a restructuring of ownership through Medline Holdings, LP, with proceeds used to acquire Common Units and repay debt. The company will maintain two classes of common stock post-offering, each with equal voting rights. The IPO is underwritten by a broad syndicate of investment banks, with potential for additional shares to be issued under the underwriters' option.
2025-11-04 · 0001193125-25-264798
S-1
filed
Initial registration statement
Initial public filing submitted to start the SEC review process.
Follows DRS/A in the pre-IPO sequence.
Class A · Exchange Nasdaq Global Select Market · Ticker MDLN · Use of proceeds To acquire Common Units from Medline Holdings for general corporate purposes, including debt repayment · Flags dual_class, units · Underwriters Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities
Medline Inc. is conducting its initial public offering (IPO) of Class A common stock, aiming to list on Nasdaq under the ticker 'MDLN.' The company plans to use proceeds from the offering to acquire Common Units from Medline Holdings, LP, which will be used for general corporate purposes, including debt repayment. The offering includes underwriters' options to purchase additional shares and involves a complex organizational structure with Class A and Class B common stock, as well as unit conversions.
2025-10-28 · 0001193125-25-253020
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Medline Inc. is conducting its initial public offering (IPO) of Class A common stock, with shares to be listed on Nasdaq under the symbol 'MDLN.' The company intends to use proceeds from the offering to acquire Common Units from Medline Holdings, LP, and to repay indebtedness. The offering involves a reorganization structure, with existing equity interests exchanged for Class A shares. The IPO price range and underwriters (including Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan) are outlined, with a focus on corporate restructuring and capital allocation.
2025-08-15 · 0000950123-25-008500
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Medline Inc. filed an Amendment No. 3 to its Form S-1 registration statement for an initial public offering (IPO) of Class A common stock. The filing outlines the proposed offering of shares, expected pricing range, Nasdaq listing, and capital structure with Class A and Class B shares. Proceeds will be used to acquire Common Units from Medline Holdings, LP, with additional funds from underwriter options directed toward pre-IPO equity repurchases. The company remains a non-accelerated filer.
2025-03-19 · 0000950123-25-003112
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS/A filing.
Medline Inc. is conducting an initial public offering (IPO) of its Class A common stock, with shares expected to be listed on Nasdaq under the symbol 'MDLN.' The offering involves converting existing equity interests in Medline Holdings, LP into Class A common stock, with proceeds used to acquire newly issued units from Medline Holdings and for general corporate purposes. The company will maintain two classes of common stock post-offering, each with equal voting rights.
2025-02-28 · 0000950123-25-002928
DRS/A
amended
Amended draft registration statement
Updated draft registration filed before the public launch.
Updates the prior DRS filing.
Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, with proceeds intended to acquire Units from Medline Holdings, LP for general corporate purposes. The company will have two classes of common stock post-offering, with Class B held by Pre-IPO Unitholders. The IPO is underwritten by Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan. The filing includes details on organizational structure, use of proceeds, and risk factors related to market conditions and reliance on key customers.
2025-01-31 · 0000950123-25-000784
DRS
filed
Draft registration statement
Draft registration filed confidentially before the public launch.
First tracked pre-IPO filing for this issuer.
Medline Inc. is conducting an initial public offering (IPO) of Class A common stock, transitioning from its predecessor entity Medline Holdings, LP. The offering aims to list shares on the Nasdaq Global Select Market under the ticker symbol 'MDLN.' Proceeds will be used to acquire Units from Medline Holdings, which will allocate funds for debt repayment and general corporate purposes. The company has two classes of stock, Class A and Class B, with equal voting rights. Prior to this offering, there was no public market for its securities.
2024-12-19 · 0000950123-24-012281
Comparable Deals
5 comparable deals
Healthcare & BiotechLast 18 months
Only 0 strict matches; expanded to 5 using nearest neighbors.
Recent News
No recent news stored for this issuer.